Cygnus GlucoWatch G2
This article was originally published in The Gray Sheet
PMA supplement approval for next-generation glucose monitor system is announced April 2. Enhancements over earlier model include a shorter waiting period between readings, an ability to display and store readings every ten minutes, and an audible alert providing "predictive" notification before a pre-set low glucose level is encountered. U.S. sales of the first-generation system, approved in March 2001, are expected to begin in the next few weeks. Introduction the G2 system will happen later this year...
You may also be interested in...
Cygnus plans to offer a pediatric version of its GlucoWatch Biographer for about $700 when shipments begin in late September
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.